Literature DB >> 11231204

Neuropsychiatric events and travel: do antimalarials play a role?

P Schlagenhauf, R Steffen.   

Abstract

Mesh:

Substances:

Year:  2000        PMID: 11231204     DOI: 10.2310/7060.2000.00069

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


× No keyword cloud information.
  6 in total

1.  Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.

Authors:  Alan M Hochberg; Ronald K Pearson; Donald J O'Hara; Stephanie J Reisinger
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

2.  Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine.

Authors:  Remington L Nevin
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-04-05       Impact factor: 4.077

Review 3.  Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives.

Authors:  Remington L Nevin; Ashley M Croft
Journal:  Malar J       Date:  2016-06-22       Impact factor: 2.979

4.  Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.

Authors:  Remington L Nevin; Jeannie-Marie Leoutsakos
Journal:  Drugs R D       Date:  2017-03

5.  The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria.

Authors:  Michael T Ambler; Lilly M Dubowitz; Ratree Arunjerdja; Eh Paw Hla; Kyaw Lay Thwai; Jacher Viladpainguen; Pratap Singhasivanon; Christine Luxemburger; François Nosten; Rose McGready
Journal:  Malar J       Date:  2009-09-02       Impact factor: 2.979

Review 6.  Rational Risk-Benefit Decision-Making in the Setting of Military Mefloquine Policy.

Authors:  Remington L Nevin
Journal:  J Parasitol Res       Date:  2015-10-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.